Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size
Immediate U.S. launch planned for dapagliflozin-metformin ER tablets; addressable market estimated at $514 millionannually
Board approves allotment of shares to promoter Shankar Varadharajan following warrant conversion under SEBI Regulation 30 disclosure
As demand for GLP-1 therapies explodes, India’s drug regulator moves to curb advertising amid rising concerns over misuse, access, and long-term impact
Move aligns global biologics identity under the Biocon Biologics brand
Institute signs four MoUs, launches two products and marks 75 years with renewed focus on lab-to-market commercialisation
The company has highlighted setbacks in Phase II studies while outlining fresh regulatory and late-stage development plans for Fibromun and Nidlegy
The showcase, running March 27–31, puts a spotlight on everything from fine lines to daily sun protection
This strategic acquisition enables CORONA Remedies to penetrate deeper into targeted specialty and offer wider accessibility
The presentations underscore the company’s deep expertise in dermatology and immunology
Subscribe To Our Newsletter & Stay Updated
